Understanding Immunity Persistence After Adolescent MenC Vaccination
Completed
- Conditions
- Antibody Persistance After Booster Dose of Men C Vaccine
- Interventions
- Other: Venepuncture and blood sample collection.
- Registration Number
- NCT01459432
- Lead Sponsor
- University of Oxford
- Brief Summary
The main purpose of this study is to evaluate the duration of immunity after a booster dose of a MenC-CRM vaccine given to adolescents between 13 and 15 years of age. Does seroprotection persist beyond teenage years and into the early twenties? This is the age group which is most likely to carry the organism and to transmit it to other members of the population. If a booster dose of MenC vaccine given to adolescents does produce protective levels of antibody which persist into early adulthood, this would strengthen the case for such a booster to be added to the UK routine immunisation schedule, to reduce the risk of a resurgence of the disease in the future.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 134
Inclusion Criteria
- Participants who completed clinical study M14P2E1
- Participant who are willing to participate and who would be expected to comply with the requirements of the protocol
- Participants who have given informed consent for participation in the study
Exclusion Criteria
- History of invasive meningococcal C disease (or any case of invasive meningococcal disease where the serotype was unknown)
- Confirmed or suspected immunosuppressive or immunodeficient conditions, including human immunodeficiency virus (HIV) infection
- Severe blood clotting disorders
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Follow-on blood sample from previous study Venepuncture and blood sample collection. -
- Primary Outcome Measures
Name Time Method Percentage of participants with rSBA titre ≥1:8 (correlate of protection). 4 months
- Secondary Outcome Measures
Name Time Method Geometric mean titre (GMT) rSBA. 4 months
Trial Locations
- Locations (1)
Oxford Vaccine Group
🇬🇧Oxford, United Kingdom